Aurinia Refocusing After Failed Effort To Find A Buyer
Kidney-focused biotech Aurinia Pharmaceuticals is hitting pause on drug development, cutting jobs and initiating a $150 million stock buyback program, the company disclosed in its year-end financial report Thursday....To view the full article, register now.
Already a subscriber? Click here to view full article